^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RAG-01

    i
    Other names: RAG-01, RAG01-40-31L
    Associations

    News

    Trials
    Company:
    Ractigen Therap
    Drug class:
    P21 inducer, RNA activator
    Associations

    News

    Trials
    6ms
    RAG-01-01: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (clinicaltrials.gov)
    P1, N=72, Recruiting, Ractigen Therapeutics. | N=15 --> 72 | Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Jun 2025 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    RAG-01
    11ms
    RNAa: Mechanisms, therapeutic potential, and clinical progress. (PubMed, Mol Ther Nucleic Acids)
    Notably, MTL-CEBPA, the first saRNA drug candidate, shows promise in hepatocellular carcinoma treatment, while RAG-01 is being explored for non-muscle-invasive bladder cancer, highlighting clinical advancements in RNAa. This review synthesizes our current understanding of the mechanisms of RNAa and highlights recent advancements in the study of mi-RNAa and the therapeutic development of saRNAs.
    Review • Journal
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    MTL-CEBPA • RAG-01
    almost2years
    A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (clinicaltrials.gov)
    P1, N=15, Recruiting, Ractigen Therapeutics. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RAG-01
    almost2years
    A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Ractigen Therapeutics.
    New P1 trial
    |
    RAG-01
    almost3years
    Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (ASCO 2023)
    These data constitute a preclinical proof-of-concept for saRNA as a novel p21-targeting modality in the treatment of cancer. The C5X5 lipid conjugate appears to be a viable approach to enhance oligonucleotide delivery and activity in bladder cancer. Preclinical safety assessment studies to enable clinical trials of RAG01-40-31L are currently underway.
    Preclinical
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • RAG1 (Recombination Activating 1)
    |
    RAG-01